Growth inhibition and chemosensitization of human carcinoma cells by human serum albumin-coated liposomal antisense oligodeoxyribonucleotide against bcl-2

References

• Pagnan G, Stuart DD, Pastorino F, Raffaghello L, Montaldo PG, Allen TM, Calabretta B, Ponzoni M. (2000). Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst 92:253–261.
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Herr W, Hänel M, Borthakur G, Frankel A, Horst HA, Martin S, Kassis J, Desjardins P, Seiter K, Fiedler W, Noppeney R, Giagounidis A, Jacob C, Jolivet J, Tallman MS, Koschmieder S. (2011). Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin Lymphoma Myeloma Leuk 11:433–438.
   PubMed Web of Science ®Google Scholar
• Herrington WG, Talbot DC, Lahn MM, Brandt JT, Callies S, Nagle R, Winearls CG, Roberts IS. (2011). Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma. Am J Kidney Dis 57:300–303.
   PubMed Web of Science ®Google Scholar
• Green DR. (2005). Apoptotic pathways: ten minutes to dead. Cell 121:671–674.
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. (2002). Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2:277–288.
   PubMed Web of Science ®Google Scholar
• Beck MT, Peirce SK, Chen WY. (2002). Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 21:5047–5055.
   PubMed Web of Science ®Google Scholar
• Sartorius UA, Krammer PH. (2002). Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97:584–592.
   PubMed Web of Science ®Google Scholar
• Zangemeister-Wittke U. (2003). Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling. Ann N Y Acad Sci 1002:90–94.
   PubMed Web of Science ®Google Scholar
• Chi KC, Wallis AE, Lee CH, De Menezes DL, Sartor J, Dragowska WH, Mayer LD. (2000). Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat 63:199–212.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Bedikian AY, Millward MJ, Conry RM, Gore ME, Pehamberger HE, Sterry W, Pavlick AC, Deconti RC, Itri LM. (2005). Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). J Clin Oncol ASCO Ann Meet Proc 23:7506.
   Google Scholar
• George J, Banik NL, Ray SK. (2009). Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res 34:66–78.
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. (2010). Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA 107:10737–10742.
   PubMed Web of Science ®Google Scholar
• Gleave ME, Monia BP. (2005). Antisense therapy for cancer. Nat Rev Cancer 5:468–479.
   PubMed Web of Science ®Google Scholar
• Arima H, Aramaki Y, Tsuchiya S. (1997). Effects of oligodeoxynucleotides on the physicochemical characteristics and cellular uptake of liposomes. J Pharm Sci 86:438–442.
   PubMed Web of Science ®Google Scholar
• Le Doan T. (2001). Cell binding and internalisation of oligonucleotides. STP Pharma Sci 11:75–82.
   Google Scholar
• Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, Yuan L, Brewster AM, Cristofanilli M, Hunt KK, Buchholz TA, Zwiebel J, Valero V, Hortobagyi GN, Esteva FJ. (2008). Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14:7909–7916.
   PubMed Web of Science ®Google Scholar
• Pastorino F, Mumbengegwi DR, Ribatti D, Ponzoni M, Allen TM. (2008). Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release 126:85–94.
   PubMed Web of Science ®Google Scholar
• Kim BK, Doh KO, Nam JH, Kang H, Park JG, Moon IJ, Seu YB. (2009). Synthesis of novel cholesterol-based cationic lipids for gene delivery. Bioorg Med Chem Lett 19:2986–2989.
   PubMed Web of Science ®Google Scholar
• Jääskeläinen I, Peltola S, Honkakoski P, Mönkkönen J, Urtti A. (2000). A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonucleotides. Eur J Pharm Sci 10:187–193.
   PubMed Web of Science ®Google Scholar
• Suh MS, Shim G, Lee HY, Han SE, Yu YH, Choi Y, Kim K, Kwon IC, Weon KY, Kim YB, Oh YK. (2009). Anionic amino acid-derived cationic lipid for siRNA delivery. J Control Release 140:268–276.
   PubMed Web of Science ®Google Scholar
• Weecharangsan W, Yu B, Zheng Y, Liu S, Pang JX, Lee LJ, Marcucci G, Lee RJ. (2009). Efficient delivery of antisense oligodeoxyribonucleotide g3139 by human serum albumin-coated liposomes. Mol Pharm 6:1848–1855.
   PubMed Web of Science ®Google Scholar
• Maurer N, Wong KF, Stark H, Louie L, McIntosh D, Wong T, Scherrer P, Semple SC, Cullis PR. (2001). Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J 80:2310–2326.
   PubMed Web of Science ®Google Scholar
• Doi S, Soda H, Oka M, Tsurutani J, Kitazaki T, Nakamura Y, Fukuda M, Yamada Y, Kamihira S, Kohno S. (2004). The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 3:1397–1402.
   PubMed Web of Science ®Google Scholar
• Ko YT, Falcao C, Torchilin VP. (2009). Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm 6:971–977.
   PubMed Web of Science ®Google Scholar
• Lima RT, Martins LM, Guimarães JE, Sambade C, Vasconcelos MH. (2004). Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 11:309–316.
   PubMed Web of Science ®Google Scholar
• Hussain S, Plückthun A, Allen TM, Zangemeister-Wittke U. (2006). Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Mol Cancer Ther 5:3170–3180.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhao G, Liu J, Ma N, Chivukula P, Perelman L, Okada K, Chen Z, Gough D, Yu L. (2009). Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J Control Release 140:277–283.
   PubMed Web of Science ®Google Scholar